Michael Avnimelech - Rekah Pharmaceutical External Director

REKA Stock  ILA 1,367  17.00  1.26%   

Director

Michael Avnimelech is External Director of Rekah Pharmaceutical Industry since 2007.
Age 68
Tenure 17 years
Phone972 3 558 1233
Webhttps://www.rekah.co.il

Rekah Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0208 % which means that it generated a profit of $0.0208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0222 %, meaning that it generated $0.0222 on every $100 dollars invested by stockholders. Rekah Pharmaceutical's management efficiency ratios could be used to measure how well Rekah Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 101.23 M in total debt with debt to equity ratio (D/E) of 1.01, which is about average as compared to similar companies. Rekah Pharmaceutical has a current ratio of 1.95, which is within standard range for the sector. Debt can assist Rekah Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Rekah Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rekah Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rekah to invest in growth at high rates of return. When we think about Rekah Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Dov KotlerBezeq Israeli Telecommunication
60
Gittit GubermanAlony Hetz Properties
61
Debbie SaperiaB Communications
48
Ytzhak EdelmanBezeq Israeli Telecommunication
64
Rami NomkinBezeq Israeli Telecommunication
68
Sharon AzrieliAzrieli Group
55
Edith LuskyBezeq Israeli Telecommunication
66
Yehudit TytelmanDelek Group
49
Naama EmanuelAlony Hetz Properties
33
Or ElovitchBezeq Israeli Telecommunication
40
Sharon AvidarB Communications
37
Itshak ForerAlony Hetz Properties
80
Adva SharvitAlony Hetz Properties
40
Tzipora CarmonAzrieli Group
63
Yehudit TytelmanZiedenbergDelek Group
46
Alejandro ElsztainDiscount Investment Corp
51
Avraham HarelDelek Group
70
Oshrit BarDavidAlony Hetz Properties
42
Joseph CiechanoverAzrieli Group
81
Mordechai KeretBezeq Israeli Telecommunication
60
Benny GabbayB Communications
49
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people. Rekah Pharmaceutical Industry (REKA) is traded on Tel Aviv Stock Exchange in Israel and employs 399 people.

Management Performance

Rekah Pharmaceutical Leadership Team

Elected by the shareholders, the Rekah Pharmaceutical's board of directors comprises two types of representatives: Rekah Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rekah. The board's role is to monitor Rekah Pharmaceutical's management team and ensure that shareholders' interests are well served. Rekah Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rekah Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Amiram Boehm, Director
Michael Avnimelech, External Director
Chaim Cohen, Chief Officer
Yaakov Elgrabli, Chief Ltd
Ilan Horesh, External Director
Arye Elgrably, CEO, Director
Yuval Bernshtein, Vice President - Finance
Haim Cohen, CFO
Orly Zilberman, External Director
Meir Melumad, Director Operations
Avraham Biger, Chairman of the Board
Mordechai Elgrabli, CEO Director
Yuval Elgrably, Deputy CEO
Yuval CPA, Chief Officer
Ronit Zelnik, Head of Projects Division
Jack Azran, Chief Technologies
Georgette Elgrabli, Director Director
Ehood Nisan, External Director
Ishay Davidi, Director
Yuval Elgrabli, Deputy Devel
Jacob Elgrably, Chief Shalpharm
Arnon Zuaretz, External Director
Menachem Dasberg, Vice President-Economic Division Manager
Georgette Elgrably, Head of Industrial Division, Director
Snir David, Vice President - Finance

Rekah Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rekah Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rekah Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rekah Pharmaceutical's short interest history, or implied volatility extrapolated from Rekah Pharmaceutical options trading.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rekah Pharmaceutical Industry. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Rekah Stock analysis

When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Please note, there is a significant difference between Rekah Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rekah Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rekah Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.